オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - vedolizumab, quantity: 119 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; histidine; histidine hydrochloride monohydrate; arginine hydrochloride; polysorbate 80; water for injections - treatment of adult patients with moderate to severe ulcerative colitis who have had an inadequate response with, lost response to, or are intolerant to either conventional therapy or a tumour necrosis factor-alpha (tnf-alpha) antagonist.,treatment of adult patients with moderate to severe crohn's disease who have had an inadequate response with, lost response to, or are intolerant to either conventional therapy or a tumour necrosis factor-alpha (tnf-alpha) antagonist.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - colchicine, quantity: 500 microgram - tablet, uncoated - excipient ingredients: magnesium stearate; sodium starch glycollate; microcrystalline cellulose; lactose monohydrate; pregelatinised maize starch - relief of pain in acute gout. colchicine should not be used unless nsaids are contraindicated, or have been used and found to lack analgesic efficacy or to have unacceptable side effects in the individual patient. colchicine is not an analgesic and does not provide relief from other types of pain.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - colchicine, quantity: 500 microgram - tablet, uncoated - excipient ingredients: sodium starch glycollate; pregelatinised maize starch; lactose monohydrate; magnesium stearate; microcrystalline cellulose - relief of pain in acute gout. colchicine should not be used unless nsaids are contraindicated, or have been used and found to lack analgesic efficacy or to have unacceptable side effects in the individual patient. colchicine is not an analgesic and does not provide relief from other types of pain.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - colchicine, quantity: 500 microgram - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; pregelatinised maize starch; microcrystalline cellulose; sodium starch glycollate - relief of pain in acute gout. colchicine should not be used unless nsaids are contraindicated, or have been used and found to lack analgesic efficacy or to have unacceptable side effects in the individual patient. colchicine is not an analgesic and does not provide relief from other types of pain.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - colchicine, quantity: 500 microgram - tablet, uncoated - excipient ingredients: sodium starch glycollate; pregelatinised starch; magnesium stearate; microcrystalline cellulose; lactose monohydrate - relief of pain in acute gout. colchicine should not be used unless nsaids are contraindicated, or have been used and found to lack analgesic efficacy or to have unacceptable side effects in the individual patient. colchicine is not an analgesic and does not provide relief from other types of pain.

マルタ - 英語 - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - mercaptopurine - tablet - mercaptopurine 50 mg - antineoplastic agents

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - azathioprine, quantity: 25 mg - tablet, film coated - excipient ingredients: purified talc; lactose monohydrate; magnesium stearate; maize starch; povidone; colloidal anhydrous silica; titanium dioxide; hypromellose; microcrystalline cellulose; peg-8 stearate - immunosuppressant antimetabolite: either alone, or more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with higher dosage and prolonged usage of corticosteroids. azathioprine, in combination with cortocosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants. azathioprine, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering from the following: severe rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis/polymyositis, autoimmune chronic active hepatitis, pemphigus vulgaris, polyarteritis nodosa, autoimmune haemolytic ana

シンガポール - 英語 - HSA (Health Sciences Authority)

shoei universal corporation pte ltd - mercaptopurine - tablet - 50 mg - mercaptopurine 50 mg

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - mercaptopurine - oral tablet - 50mg